CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Trimetazidine +1 moredrug
Likely dose
Trimetazidine 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06459193
NCT06459193Phase 2Completed
CompareCT.gov

Evaluation of Trimetazidine in Alleviating Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients

Minia University·interventional·Posted Jun 14, 2024·Updated Mar 30, 2025

In Brief

A Phase 2 clinical trial evaluating Trimetazidine and Placebo for Peripheral Neuropathy Due to Chemotherapy. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This proof-of-concept study evaluated the effect of Trimetazidine on the incidence of paclitaxel-induced peripheral neuropathy in patients with breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Neuropathy Due to Chemotherapy
CountriesEgypt
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedJun 14, 2024
Enrollment StartJun 23, 2024
Primary CompletionJan 28, 2025
Study CompletionMar 27, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.1 years ago

Interventions

Trimetazidinedrug

Trimetazidine 35 mg tab once daily

Placebodrug

Placebo once daily